AnteoTech Limited Stock

Equities

ADO

AU000000ADO8

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:45 2024-04-19 am EDT 5-day change 1st Jan Change
0.023 AUD +4.55% Intraday chart for AnteoTech Limited -4.17% -36.11%
Sales 2022 761K 488K Sales 2023 366K 235K Capitalization 82M 52.64M
Net income 2022 -10M -6.42M Net income 2023 -12M -7.7M EV / Sales 2022 158 x
Net cash position 2022 9.07M 5.82M Net cash position 2023 1.41M 908K EV / Sales 2023 220 x
P/E ratio 2022
-12 x
P/E ratio 2023
-6.33 x
Employees 99
Yield 2022 *
-
Yield 2023
-
Free-Float 90.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.55%
1 week-4.17%
Current month-37.84%
1 month-42.50%
3 months-37.84%
6 months-20.69%
Current year-36.11%
More quotes
1 week
0.02
Extreme 0.021
0.02
1 month
0.02
Extreme 0.021
0.04
Current year
0.02
Extreme 0.021
0.04
1 year
0.02
Extreme 0.021
0.06
3 years
0.02
Extreme 0.021
0.50
5 years
0.01
Extreme 0.01
0.50
10 years
0.01
Extreme 0.008
0.50
More quotes
Managers TitleAgeSince
Founder - 08-12-31
Chief Executive Officer - 22-10-03
Director of Finance/CFO - 23-08-27
Members of the board TitleAgeSince
Director/Board Member - 21-08-31
Director/Board Member - 21-08-31
Chief Executive Officer - 22-10-03
More insiders
Date Price Change Volume
24-04-19 0.023 +4.55% 451 158
24-04-18 0.022 0.00% 5,556,805
24-04-17 0.022 -4.35% 3,087,731
24-04-16 0.023 +4.55% 3,783,499
24-04-15 0.022 -8.33% 6,756,642

Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT

More quotes
AnteoTech Limited is an Australia-based surface chemistry company. The principal activities of the Company consist of research, development and commercialization of technologies with surface management applications. The activities are primarily focused on the commercialization of these technologies across applications in the Life Science and Clean Energy Technology markets. Its lead product, AnteoX, provides significant improvement in anode performance and the Company has partnered with global suppliers in lithium-ion battery manufacturing. The life sciences division services the point of care and diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy. It also offers bioconjugation and assay development services to assist point of care and diagnostics researchers and manufacturers in product development. It also offers ready-to-use kits.
More about the company

Annual profits - Rate of surprise